Bausch + Lomb (BLCO) announced an affiliate has acquired Whitecap Biosciences which is currently developing two innovative therapies for ...

Bausch + Lomb (BLCO) announced the commercial launch of the enVista Aspire monofocal and toric intraocular lenses in the European Union after ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, and Glaucoma Research Foundation (GRF), a national nonprofit ...

Evercore ISI lowered the firm’s price target on Bausch + Lomb (BLCO) to $22 from $25 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of their value on a report that a joint takeover bid for the group is in trouble. The Financial Times has said that ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bausch + Lomb has bought US and Canadian rights to a potential biosimilar competitor to Novartis’ Lucentis from Germany’s Stada, as the blockbuster approaches the end of its patent ...

3-in-1 Magnifier: Flexible gooseneck frees your hands. It not only can be hung around your neck to adjust different directions and heights, you will not feel tired even after a long time of use.

Magnification power of the head magnifier: 1.0X, 1.5X, 2.0X, 2.5X, 3.5X. Scratch-resistant acrylic reduces weight. COMFORTABLE AND EASY TO USE: Comfortable eyeglass frame with rubber nose-pads ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, and Glaucoma Research ...

After hours: January 8 at 5:16:11 p.m. EST ...